CYFIP2

Chr 5AD

cytoplasmic FMR1 interacting protein 2

Also known as: DEE65, EIEE65, PIR121

Predicted to enable small GTPase binding activity. Involved in several processes, including cell-cell adhesion; positive regulation of proteolysis; and regulation of postsynapse assembly. Located in perinuclear region of cytoplasm and synapse. Part of SCAR complex. Implicated in developmental and epileptic encephalopathy 65. [provided by Alliance of Genome Resources, Jul 2025]

OMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.091 OMIM phenotype
Clinical SummaryCYFIP2
🧬
Gene-Disease Validity (ClinGen)
complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
22 unique Pathogenic / Likely Pathogenic· 438 VUS of 1174 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.09LOEUF
pLI 1.000
Z-score 7.43
OE 0.03 (0.010.09)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
6.01Z-score
OE missense 0.37 (0.340.41)
274 obs / 731.7 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios?
LoF OE?0.03 (0.010.09)
00.351.4
Missense OE?0.37 (0.340.41)
00.61.4
Synonymous OE?1.01
01.21.6
LoF obs/exp: 2 / 68.2Missense obs/exp: 274 / 731.7Syn Z: -0.16
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveCYFIP2-related epileptic encephalopathy, early infantileOTHERAD

This gene — mechanism propensity

DN
0.2997th %ile
GOF
0.4875th %ile
LOF
0.73top 10%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · LOEUF 0.09
GOF1 literature citation · 91% of P/LP are missense

Literature Evidence

GOFOur findings suggest that de novo Arg87 variants in CYFIP2 have gain-of-function effects on the WAVE signaling pathway and are associated with severe neurological disorders.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 29534297

ClinVar Variant Classifications

1174 submitted variants in ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic16
VUS438
Likely Benign589
Benign66
Conflicting33
6
Pathogenic
16
Likely Pathogenic
438
VUS
589
Likely Benign
66
Benign
33
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
5
0
0
6
Likely Pathogenic
1
15
0
0
16
VUS
30
377
29
2
438
Likely Benign
6
57
240
286
589
Benign
1
3
37
25
66
Conflicting
33
Total394573063131,148

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

16 pathogenic / likely-pathogenic (of 25) ClinVar copy-number / structural variants overlap CYFIP2 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CYFIP2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →